About 5 results found for searched term "VcMMAE" (0.906 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9216 | VcMMAE | Microtubule |
| MC-VC-PAB-MMAE; MMAE Vc linker; MC-Val-Cit-PAB-MMAE | ||
| VcMMAE is an anti-mitotic compound, monomethylauristatin E (MMAE), linked by a lysosomal cleavable dipeptide, valine-citrulline (VC). *The compound is unstable in solutions, freshly prepared is recommended | ||
| M24824 | Sirtratumab vedotin | Drug-Linker Conjugates for ADC |
| AGS15E; ASG-15ME; 1vcMMAE | ||
| Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker. | ||
| M58984 | Glembatumumab vedotin | Antibody-Drug Conjugates (ADCs) |
| CDX-011; CR011-vcMMAE | ||
| Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects. | ||
| M25284 | Brentuximab vedotin | Drug-Linker Conjugates for ADC |
| Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. | ||
| M59066 | Ozuriftamab vedotin | Antibody-Drug Conjugates (ADCs) |
| BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC | ||
| Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
